File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children

TitleImmunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children
Authors
KeywordsChildren
Influenza vaccine
Intradermal
Reduced dosage
Issue Date2007
PublisherAmerican Academy of Pediatrics. The Journal's web site is located at http://pediatrics.aappublications.org/
Citation
Pediatrics, 2007, v. 119 n. 6, p. 1076-1082 How to Cite?
AbstractOBJECTIVES. We conducted this study to test the hypothesis that intradermal influenza vaccination at one fifth of a standard dose elicits comparable immunogenicity to full-dose intramuscular vaccination in children. PATIENTS AND METHODS. We conducted a randomized, open-label study in 112 healthy children aged 3 to <18 years to compare the immunogenicity and safety of intradermal vaccination at one fifth of a dose with standard intramuscular vaccination. Analyses of hemagglutination inhibition antibody titers to each antigen in each group included geometric mean titers before and 21 days after vaccination, fold increase in geometric mean titers after vaccination, seroprotection rate, and seroconversion rate. RESULTS. The mean age of the subjects was 10.11 ± 4.04 years in the intradermal vaccination group and 10.57 ± 3.91 years in the intramuscular group. Intradermal vaccination was safe. Induration and mild erythema at the injection site were reported at 25% and 57%, respectively, in the intradermal group. Fold increase of geometric mean titers against influenza A/Caledonia was robust in both groups (11.1-fold and 12.9-fold increase in the intramuscular and intradermal groups, respectively), whereas that for B/Shandong was more modest (4.3- 4.4). Both approaches elicited very high geometric mean titers against influenza A/Panama: 1360.5 and 893.9 for the intramuscular and intradermal groups, respectively, but because the prevaccination antibody titers were high, the fold increase of geometric mean titers was only 4.5 and 2.6, respectively. CONCLUSION. The immunogenicity of one fifth of a dose of influenza vaccine delivered by the intradermal route is comparable to the standard-dose intramuscular vaccination in children as young as 3 years of age. Copyright © 2007 by the American Academy of Pediatrics.
Persistent Identifierhttp://hdl.handle.net/10722/79272
ISSN
2015 Impact Factor: 5.196
2015 SCImago Journal Rankings: 3.226
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChiu, SSen_HK
dc.contributor.authorPeiris, JSMen_HK
dc.contributor.authorChan, KHen_HK
dc.contributor.authorWong, WHSen_HK
dc.contributor.authorYu, LLen_HK
dc.date.accessioned2010-09-06T07:52:40Z-
dc.date.available2010-09-06T07:52:40Z-
dc.date.issued2007en_HK
dc.identifier.citationPediatrics, 2007, v. 119 n. 6, p. 1076-1082en_HK
dc.identifier.issn0031-4005en_HK
dc.identifier.urihttp://hdl.handle.net/10722/79272-
dc.description.abstractOBJECTIVES. We conducted this study to test the hypothesis that intradermal influenza vaccination at one fifth of a standard dose elicits comparable immunogenicity to full-dose intramuscular vaccination in children. PATIENTS AND METHODS. We conducted a randomized, open-label study in 112 healthy children aged 3 to <18 years to compare the immunogenicity and safety of intradermal vaccination at one fifth of a dose with standard intramuscular vaccination. Analyses of hemagglutination inhibition antibody titers to each antigen in each group included geometric mean titers before and 21 days after vaccination, fold increase in geometric mean titers after vaccination, seroprotection rate, and seroconversion rate. RESULTS. The mean age of the subjects was 10.11 ± 4.04 years in the intradermal vaccination group and 10.57 ± 3.91 years in the intramuscular group. Intradermal vaccination was safe. Induration and mild erythema at the injection site were reported at 25% and 57%, respectively, in the intradermal group. Fold increase of geometric mean titers against influenza A/Caledonia was robust in both groups (11.1-fold and 12.9-fold increase in the intramuscular and intradermal groups, respectively), whereas that for B/Shandong was more modest (4.3- 4.4). Both approaches elicited very high geometric mean titers against influenza A/Panama: 1360.5 and 893.9 for the intramuscular and intradermal groups, respectively, but because the prevaccination antibody titers were high, the fold increase of geometric mean titers was only 4.5 and 2.6, respectively. CONCLUSION. The immunogenicity of one fifth of a dose of influenza vaccine delivered by the intradermal route is comparable to the standard-dose intramuscular vaccination in children as young as 3 years of age. Copyright © 2007 by the American Academy of Pediatrics.en_HK
dc.languageengen_HK
dc.publisherAmerican Academy of Pediatrics. The Journal's web site is located at http://pediatrics.aappublications.org/en_HK
dc.relation.ispartofPediatricsen_HK
dc.subjectChildrenen_HK
dc.subjectInfluenza vaccineen_HK
dc.subjectIntradermalen_HK
dc.subjectReduced dosageen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAntibodies, Viral - biosynthesis - blooden_HK
dc.subject.meshChilden_HK
dc.subject.meshChild, Preschoolen_HK
dc.subject.meshErythema - epidemiology - immunologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInfluenza Vaccines - administration & dosage - adverse effects - immunologyen_HK
dc.subject.meshInjections, Intradermalen_HK
dc.subject.meshInjections, Intramuscularen_HK
dc.subject.meshMaleen_HK
dc.subject.meshPain - epidemiology - immunologyen_HK
dc.subject.meshVaccination - adverse effectsen_HK
dc.titleImmunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy childrenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1120-7507&volume=119&spage=1076&epage=1082&date=2007&atitle=Immunogenicity+and+Safety+of+Intradermal+Influenza+Immunization+at+a+Reduced+Dose+in+Healthy+Childrenen_HK
dc.identifier.emailChiu, SS: ssschiu@hku.hken_HK
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hken_HK
dc.identifier.authorityChiu, SS=rp00421en_HK
dc.identifier.authorityPeiris, JSM=rp00410en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1542/peds.2006-3176en_HK
dc.identifier.pmid17545373-
dc.identifier.scopuseid_2-s2.0-34249880784en_HK
dc.identifier.hkuros127694en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34249880784&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume119en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1076en_HK
dc.identifier.epage1082en_HK
dc.identifier.eissn1098-4275-
dc.identifier.isiWOS:000246948900005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChiu, SS=7202291500en_HK
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_HK
dc.identifier.scopusauthoridChan, KH=7406034307en_HK
dc.identifier.scopusauthoridWong, WHS=13310222200en_HK
dc.identifier.scopusauthoridYu, LL=8617704200en_HK
dc.identifier.citeulike2648132-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats